Wouldn’t this be ironic?

Wouldn’t this be ironic?

The best part of the soap opera going on at Sanofi (NYSE:SNY) is the daily scuttlebutt about who will be the new CEO. It seems that people are ignoring the fact that the Board must also find someone to fill the Chairman position; it’s almost as if this position is an afterthought. Be that as it may be two names keep popping up as the leading candidates to replace Chris Viehbacher and both have a diabetes connection.

Diabetic Investor is hearing that Pascal Soriot Executive Director and Chief Executive Officer at AstraZeneca (NYSE:AZN) and Enrique A. Conterno Senior Vice President and President, Lilly (NYSE:LLY) Diabetes are being seriously considered as the new CEO.

Given that one of the reasons Viehbacher got canned was because he wasn’t “French” enough Mr. Soriot would appear to have an edge over Mr. Conterno who according to his bio; “He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.” Mr. Soriot also has history with Sanofi as he served as Senior Vice President of Commercial Operations, United States of Sanofi-Aventis back in August 2004 and Chief Operating Officer back in 2002.

Wouldn’t it be ironic if say both of these gentlemen were brought in, one as CEO the other as Chairman. Quite frankly Diabetic Investor is praying for this exact scenario as next to the MannKind (NASDAQ:MNKD) Sanofi partnership such a move would provide for some of the best copy ever. Perhaps the only better scenario would be if the Board hired a true Frenchman Pepe le Pew as CEO or Chairman.

Think about this for a moment but should one or both be brought in the deals that become possible. Think of the irony that after turning down nearly $120 billion from Pfizer (NYSE:PFE) Mr. Soriot as Sanofi CEO goes after his old company. Or what about Mr. Conterno who’s been spread heading Lilly’s diabetes transition gets the job and does the exact same thing. The mere fact that these names are being thrown around would seem to indicate that the Sanofi Board has decide to go big rather than go home when it comes to diabetes.

Still we must admit that while we’re not a lover of skunks Pepe le Pew would make an excellent choice as this amorous character would bring a certain Je ne sais quoi to the executive suite in Paris. On with the revolution Viva La France!